Applications are now being accepted for a pair of grants offered by the Epigenetic Therapies SPORE. These $50,000 grants are awarded through its Career Enhancement Program (CEP) and Developmental Research Program (DRP) to scientists interested in developing epigenetic therapies for the treatment of cancer. These grants are open to applicants from all organizations nationwide, and pre-proposals will be accepted through March 15, 2024. Full proposals will be due on May 1, 2024.
Established in August of 2021 by the National Cancer Institute (NCI), the Epigenetic Therapies SPORE is a collaboration between the Coriell Institute for Medical Research and Van Andel Institute, led by highly respected scientists — Dr. Jean-Pierre Issa, Dr. Stephen Baylin, and Dr. Peter A. Jones. The SPORE team is developing epigenetic therapies to improve the quality of life and survival of cancer patients, through basic, translational, and clinical research.
The CEP and DRP programs are offerings of the SPORE research project and aim to encourage early career, mid-level, and established scientists to pursue research in epigenetic therapies.
The SPORE’s CEP is designed for scientists starting their research careers and is also open to established investigators who would like to explore and pivot their research into cancer epigenetics. The eligibility for DRP is focused on scientists developing pilot projects that might later be developed into full independent research projects or even be included in the Epigenetics SPORE itself.
The Epigenetic Therapies SPORE seeks to diversify the field of research and aid in the persistent challenges presented by inequalities in PI levels, gender, ethnicity, and funding; therefore, we place great emphasis on recruiting and retaining qualified women, minorities, and underserved investigators.
More information on the application process can be found online for the Career Enhancement Program and for the Development Research Program and related questions can be forwarded to Sonata M. Stevenson, Epigenetic Therapies SPORE Administrator at sstevenson@coriell.org or 856-668-2077.
*Acknowledgment: 100% of the Epigenetics SPORE CEP/DRP grants in the amount of $50,000 each is supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award number P50CA254897.
About the Coriell Institute for Medical Research
Founded in 1953, the Coriell Institute for Medical Research is a nonprofit research institute dedicated to improving human health through biomedical research. Coriell scientists lead research in personalized medicine, cancer biology, epigenetics, and the genomics of opioid use disorder. Coriell also hosts one of the world's leading biobanks—comprised of collections for the National Institutes of Health, disease foundations and private clients—and distributes biological samples and offers research and biobanking services to scientists around the globe. To facilitate drug discovery and disease study, the Institute also develops and distributes collections of induced pluripotent stem cells. For more information, visit Coriell.org.
